Slide Down
Explore more

Global Leader in 3D Printing Pharmaceuticals

Creating New Dimensions

About Triastek

Global leader in 3D printing pharmaceuticals
Pioneer of new digital pharmaceutical processes

Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medicines through digital product development and continuous manufacturing.

Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals.

Our vision is to become the world's most influential intelligent pharmaceutical enterprise.

Global leader in 3D printing pharmaceuticals
Pioneer of new digital pharmaceutical processes

Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide...

Explore more

Last updated: December 2023

    213

    Patent
    Applications

    68

    Granted
    Patents

    10

    Territories

Melt Extrusion Deposition
3D Printing Process

Melt Extrusion Deposition (MED®) 3D printing is a process that continuously converts powder feedstocks into softened/molten states followed by precise layer-by-layer deposition to produce objects with well-designed geometric structures.

Business Model

Product Partnership

    License-out

Technology Platform Partnership

    Research
    Collaboration

    Technology Platform
    Collaboration

    Products
    Co-development

Explore more

Triastek’s 3D Microstructure Delivery Technology Platform

Triastek has developed multiple 3D microstructure delivery technology platforms that enable precise control when, where and how much medicine is released in the body, allowing for unlimited possibilities in the creation of solid dosage forms.

Triastek has completed 70+ novel dosage form designs and 10+ human data validations.

    3DμS®-DR

    3D Microstructure for Delayed Release

    3DμS®-SE

    3D Microstructure for Solubility Enhancement

    3DμS®-CT

    3D Microstructure for Colon Targeting

    3DμS®-GR

    3D Microstructure for Gastric Retention

    3DμS®-OP

    3D Microstructure for Oral Peptide

Pipeline

Product /
Indication
Key Differentiation /
Platform
Preclinical
IND
Pilot-Scale
Clinical
Trials
Pivotal
Clinical
Trials
NDA
Partner
Triastek
Rights
T19
RA, PsA, AS
Efficacy Improvement
3DμS®-DR
2025E
Global
T20
AF, VTE
Adherence Improvement
3DμS®-SE
US
Global
T21
UC
Safety Improvement
3DμS®-CT
US
Global
T22
PAH
Adherence Improvement
3DμS®-GR
Ex-East Asia
Not Disclosed
Adherence Improvement & Treatable Population Expansion
3DμS®-OP
Global

RA: Rheumatoid Arthritis; PsA: Psoriatic Arthritis; AS: Ankylosing Spondylitis; AF: Atrial Fibrillation; VTE: Venous Thromboembolism; UC: Ulcerative Colitis; PAH: Pulmonary Arterial Hypertension